Panelists discuss how KEYNOTE-799 provides updated data on safety, toxicity, positive response rates, and median survival rates for both squamous and nonsquamous non–small cell lung cancer treatments.
ELCC 2025 Highlights
Panelists discuss how the practice-changing LAURA study demonstrates the critical importance of next-generation sequencing in guiding therapeutic decisions for non–small cell lung cancer (NSCLC) patients.
Panelists discuss how the MARIPOSA study design demonstrates an overall survival benefit while effectively preventing adverse events in patients.
Panelists discuss how response rates, progression-free survival, and overall survival data presented at the European Lung Cancer Conference (ELCC 2025) demonstrate meaningful clinical outcomes while highlighting important safety considerations for patients.
The Oncology Brothers provide a comprehensive recap of the key highlights presented at the European Lung Cancer Conference (ELCC 2025) along with their expert final thoughts and clinical interpretations.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma
3
Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma
4
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
5
